Llwytho...
Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
Even though classical Hodgkin lymphoma is highly curable, the outcome of patients with a refractory or relapsed disease has been disappointing. Multiple lines of therapy are available for patients after their first failure, and most respond to subsequent therapies. However, there is a sizable propor...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | World J Oncol |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Elmer Press
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8297052/ https://ncbi.nlm.nih.gov/pubmed/34349851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/wjon1388 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|